Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
03-05 June, 2026
Peptide Therapeutics F...Peptide Therapeutics Forum 2026
Not Confirmed
Not Confirmed
04-05 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
03-05 June, 2026
Peptide Therapeutics F...Peptide Therapeutics Forum 2026
Industry Trade Show
Not Confirmed
04-05 June, 2026
Digital content
NEWS #PharmaBuzz
22 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/duchesnay-and-peripharm-emphasize-the-need-to-update-regulatory-and-reimbursement-policies-to-improve-access-to-innovations-in-womens-health-302749510.html
07 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/duchesnay-launches-a-contraceptive-vaginal-system-that-can-be-used-for-up-to-a-full-year-302735861.html
18 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/the-community-support-by-duchesnay-pharmaceutical-group-is-a-year-round-effort-from-all-employees-302645279.html
09 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/analog-pharma-canada-launches-its-first-product-on-the-canadian-market-302547765.html
13 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/duchesnay-usa-and-mymenopauserx-join-in-a-partnership-to-offer-expert-consultations-for-menopausal-women-302452905.html
27 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/duchesnay-pharmaceutical-group-recognized-for-commitment-to-well-being-of-its-employees-as-winner-of-2025-healthiest-workplace-award-302412602.html
Drugs in Development
Details:
Ringza (Segesterone Acetate) is a hormone drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of pregnancy.
Lead Product(s): Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Ringza
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Population Council
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2026
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Population Council
Deal Size : Inapplicable
Deal Type : Inapplicable
Duchesnay Launches Contraceptive Vaginal System for Year-long Use
Details : Ringza (Segesterone Acetate) is a hormone drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of pregnancy.
Product Name : Ringza
Product Type : Hormone
Upfront Cash : Inapplicable
April 07, 2026
Details:
PHEBURANE® (sodium phenylbutyrate) is indicated adjunctive therapy to standard of care, which includes dietary management, for chronic management of adult and pediatric patients with UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Brand Name: Pheburane
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2022
Lead Product(s) : Sodium Phenylbutyrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHEBURANE® (sodium phenylbutyrate) is indicated adjunctive therapy to standard of care, which includes dietary management, for chronic management of adult and pediatric patients with UCDs.
Product Name : Pheburane
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2022
Details:
Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.
Lead Product(s): Dequalinium Chloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vablys
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 21, 2022
Lead Product(s) : Dequalinium Chloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vablys® (dequalinium chloride vaginal tablets), is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women under 55 years of age.
Product Name : Vablys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2022
Details:
Doxylamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Morning Sickness.
Lead Product(s): Doxylamine Succinate,Pyridoxine Hydrochloride
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Health Decisions
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2022
Lead Product(s) : Doxylamine Succinate,Pyridoxine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Health Decisions
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescen...
Details : Doxylamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Morning Sickness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2022
Details:
As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.
Lead Product(s): Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Annovera
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Population Council
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2020
Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Population Council
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
Details : As part of the agreement, Duchesnay will explore opportunities to register ANNOVERA with local regulatory agencies in these regions and will invest in the Population Council’s research activities to develop new innovative contraceptive products.
Product Name : Annovera
Product Type : Steroid
Upfront Cash : Undisclosed
November 30, 2020
Details:
The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of their own home.
Lead Product(s): Ospemifene
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Plushcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 19, 2020
Lead Product(s) : Ospemifene
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Plushcare
Deal Size : Undisclosed
Deal Type : Partnership
Details : The aim of this partnership is to provide Duchesnay USA's Osphena® (ospemifene) to women suffering from vaginal symptoms related to menopause, with the possibility of having this conversation with a healthcare provider in the comfort and privacy of the...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 19, 2020
Details:
PregVit (Folic Acid) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pregnancy.
Lead Product(s): Folic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: PregVit
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Recipient: The Hospital for Sick Children
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 25, 2014
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Recipient : The Hospital for Sick Children
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimizing Periconceptional and Prenatal Folic Acid Supplementation
Details : PregVit (Folic Acid) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pregnancy.
Product Name : PregVit
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 25, 2014
Details:
PregVit (Folic Acid) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pregnancy.
Lead Product(s): Folic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: PregVit
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Recipient: The Hospital for Sick Children
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 24, 2014
Lead Product(s) : Folic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Recipient : The Hospital for Sick Children
Deal Size : Inapplicable
Deal Type : Inapplicable
Improving Multivitamin Supplementation to Pregnant Women
Details : PregVit (Folic Acid) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pregnancy.
Product Name : PregVit
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 24, 2014
Details:
Doxylamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Morning Sickness.
Lead Product(s): Doxylamine Succinate,Pyridoxine Hydrochloride
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Premier Research Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2014
Lead Product(s) : Doxylamine Succinate,Pyridoxine Hydrochloride
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnanc...
Details : Doxylamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Morning Sickness.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2014
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Inspections and registrations
ABOUT THIS PAGE
Share 
